ANI Pharmaceuticals on July 18, 2016 announced the immediate launch of its generic of Nilandron (nilutamide) tablets following the Food and Drug Administration’s approval of the drug. This is the first generic of the drug, which is indicated to treat metastatic prostate cancer in combination with surgical castration.

Arthur S. Przybyl, ANI’s President and CEO stated, “The nilutamide approval exemplifies ANI’s strategic focus to introduce high barrier niche generic products.  We are excited to have secured approval for a first-to-market generic that represents ANI’s second entry into the anti-cancer market and leverages our specialized high-potent manufacturing capability at our plant inBaudette, MN.

“The nilutamide launch is ANI’s eighth new product launch since the beginning of the second quarter of 2016. The previously-announced launches were hydrocortisone rectal cream 1% and 2.5%, Inderal® LA capsules, propranolol ER capsules, mesalamine enema, fenofibrate 50mg and 150mg capsules, oxycodone 5mg capsules, and hydroxyprogesterone caproate injection USP 250mg/mL.  The launches are the direct result of internal product development, acquisitions and partnered distribution and represent the combined strategic approach to ANI’s product line expansion.”

ANI Pharmaceuticals, Inc. is looking for people to join their fast growing pharmaceutical company! View current job opportunities at ANI Pharmaceuticals, Inc. by clicking here. ANI offers full-time employees competitive wages, a progressive work environment with career progression and advancement opportunities, Health, Dental, Vision and Life Insurance, Short-term and Long-term Disability, 401K with Company Match, Employee Stock Purchase Plan, Paid Time Off, and 11 Company Paid Holidays, and last but certainly not least, the opportunity to work with the best of the best, and grow and develop right along with the company.

Recommended Posts